{
    "ucits": true,
    "type": "ETP",
    "leverage": true,
    "derivatives": true,
    "swaps": false,
    "inverse": false,
    "replication_method": "synthetic",
    "complex_factors": "Leverage, Synthetic replication, Derivative use, Daily rebalancing compounding effect, High risk profile",
    "classification": "complex",
    "supporting_data": "The product is a Collateralised Exchange Traded Security (ETP) aiming to provide 2x daily leveraged exposure to JPMorgan Chase & Co. equity, tracking a leveraged index. It uses leverage explicitly (2x), which is beyond UCITS limits for leverage and thus a complexity factor. The product employs synthetic replication via derivatives to achieve its objective, involving daily rebalancing and compounding effects that cause returns over periods longer than one day to deviate from simple multiples of the underlying asset's return. This introduces complexity in understanding payoff and risk. The product carries a highest risk class (7/7) on the risk scale, reflecting high volatility and risk of significant loss. The structure involves collateral accounts and margining, indicating counterparty and collateral risk typical of synthetic products. The intended retail investor is described as sophisticated, able to monitor frequently, and aware of the risks of leverage and compounding, implying complexity beyond basic investor understanding. The product is not capital protected and may result in total loss. These features align with MiFID II criteria for complex instruments: use of derivatives integral to strategy, leverage beyond UCITS limits, synthetic replication, and payoff structures difficult for retail investors to understand. Therefore, it must be classified as complex under MiFID II rules and requires an appropriateness assessment before sale to retail clients."
}